dc.contributor.author | Chrisanthar, Ranjan | nb_NO |
dc.contributor.author | Knappskog, Stian | nb_NO |
dc.contributor.author | Løkkevik, Erik | nb_NO |
dc.contributor.author | Anker, Gun Birgitta | nb_NO |
dc.contributor.author | Østenstad, Bjørn | nb_NO |
dc.contributor.author | Lundgren, Steinar | nb_NO |
dc.contributor.author | Risberg, Terje | nb_NO |
dc.contributor.author | Mjaaland, Ingvil | nb_NO |
dc.contributor.author | Skjønsberg, Gudbrand | nb_NO |
dc.contributor.author | Aas, Turid | nb_NO |
dc.contributor.author | Schlichting, Ellen | nb_NO |
dc.contributor.author | Fjøsne, Hans Erikssønn | nb_NO |
dc.contributor.author | Nysted, Arne | nb_NO |
dc.contributor.author | Lillehaug, Johan R. | nb_NO |
dc.contributor.author | Lønning, Per Eystein | nb_NO |
dc.date.accessioned | 2014-12-19T14:18:30Z | |
dc.date.available | 2014-12-19T14:18:30Z | |
dc.date.created | 2012-08-22 | nb_NO |
dc.date.issued | 2011 | nb_NO |
dc.identifier | 546109 | nb_NO |
dc.identifier.issn | 1932-6203 | nb_NO |
dc.identifier.uri | http://hdl.handle.net/11250/263530 | |
dc.language | eng | nb_NO |
dc.publisher | Norges teknisk-naturvitenskapelige universitet, Det medisinske fakultet, Institutt for kreftforskning og molekylær medisin | nb_NO |
dc.title | Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.source.pagenumber | 1-10 | nb_NO |
dc.source.volume | 6 | nb_NO |
dc.source.journal | PLoS ONE | nb_NO |
dc.source.issue | 4 | nb_NO |
dc.identifier.doi | 10.1371/journal.pone.0019249 | nb_NO |
dc.contributor.department | Norges teknisk-naturvitenskapelige universitet, Det medisinske fakultet, Institutt for kreftforskning og molekylær medisin | nb_NO |